GENESIS Biomed supports the creation of BetaScreen, the first spin-off of the Pasqual Maragall Foundation

by GENESIS Biomed

5 years ago
BetaScreen, GENESIS Biomed, Barcelonaβeta Brain Research Center, biomarkers, Alzheimer

BetaScreen’s technology is based on an algorithm capable of interpreting image biomarkers from Magnetic Resonance and CT scans, which allows to identify the presence of abnormal levels of Alzheim...

Opening of the Mowoot Crowdfunding campaign with the participation of EIT Health

by GENESIS Biomed

5 years ago
MOWOOT, crowdfunding, GENESIS Biomed, EIT Health

For the first time since its foundation, EIT Health offers the first pan-European crowdfunding platform dedicated exclusively to the healthcare sector. T

Interview Xavier Canals – Director Tecno-med Ingenieros, Vice-president SEEIC and independent consultant in Healthcare Technology

by GENESIS Biomed

5 years ago
Xavier Canals

Xavier Canals: “Sometimes there is a very weak line to classify whether an-app is a medical application, SaMD, or an application for wellbeing”.

The mHealth boom in mental health

by GENESIS Biomed

5 years ago
GENESIS Biomed, eB2, FARMALARM, mHealth, mental health

GENESIS Biomed is involved in eB2 and FARMALARM mHealth projects.

Progress in the maturity of the start-ups: the clinical phases

by GENESIS Biomed

5 years ago
start-ups, Oxolife, Peptomyc, aptaTargets, GENESIS Biomed, clinical phases, drug

The start-ups Oxolife, Peptomyc and aptaTargets, with which GENESIS Biomed collaborates, are advancing in their maturity with the initiation and development of clinical phases and are approaching an e...

Interview Andreu Climent – Associate Founder and CEO of Corify Care

by GENESIS Biomed

5 years ago
Andreu Climent, GENESIS Biomed, Corify Care

Andreu Climent: “Every time our device is used on a patient, and the patient is cured, it is an incredible adrenaline rush”

Los retos de la sanidad

by GENESIS Biomed

5 years ago
GENESIS Biomed, Sanidad

Hoy publicamos en nuestra web este vídeo en que os acercamos las enseñanzas y consejos que nos ha ofrecido Lluís Triquell, consultor independiente de Salud y miembro del Business Advisory Board GEN...

A FECYT report concludes that the entire innovation incentive scheme needs to be redesigned

by GENESIS Biomed

5 years ago
THINK TANK, FECYT, industrial and intellectual protection

GENESIS Biomed has participated in the preparation of the THINK TANK report “Patenting and/or publishing” by the FECYT, which covers the debate on publishing research or its transfer and exploitat...

Corify Care raises €2.35M to translate its cardiac mapping technology to the market

by GENESIS Biomed

5 years ago
Corify Care, Genesis Biomed, cardiac mapping, technology

Corify Care is developing ACORYS®, a non-invasive cardiac mapping medical device to transform the cardiac arrhythmia treatment process.

Interview Dr. Manuel Desco – Professor of Radiology at the Carlos III University and Head of Experimental Medicine and Surgery at the Gregorio Marañón Hospital

by GENESIS Biomed

5 years ago
GENESIS Biomed, technology, biomedical imaging, biomedical engineering, Manuel Desco

Manuel Desco has the Degree and PhD in Medicine and is Nuclear Medicine Specialist and Telecommunications Engineer. He is currently Professor of Bioengineering at the Carlos III University and Head of...

Nace Endolipid Therapeutics, la spin-off de Vall d’Hebron y GENESIS Ventures que desarrolla una nueva estrategia para reducir la grasa visceral y subcutánea

by GENESIS Biomed

5 years ago
dieta saludable, Endolipid Therapeutics, grasa visceral

La acumulación de grasa ectópica y especialmente en el abdomen (grasa visceral) es un factor independiente de riesgo cardiovascular y también se asocia a hígado graso no alcohólico, una condici...

Algorithms and Image Biomarkers. Radiomics as another piece of precision oncology

by GENESIS Biomed

5 years ago
precision oncology, Image Biomarkers, Radiomics, Cancer

Cancer is a disease with a high incidence rate among the population (442.4 cases per 100,000 people). And its mortality rate stands at 158.3 per 100,000 people. By 2040, the number of new cancer cases...